Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib in gastric cancer
ChiCTR1800019058Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Inner Mongolia Medical University
- Start
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Affiliated Hospital of Inner Mongolia Medical University. Primary endpoints: progression-free survival, recurrence-free survival and 1 more. Started Nov 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800019058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019058.